GENOMIC BIOMARKER MARKET INTRODUCTION

A genomic biomarker is a DNA or RNA characteristic that indicates normal biological processes, pathogenic processes, and/or responsiveness to therapeutic or other treatments. These quantifiable variables offer quantifiable proof of treatment effectiveness, predict treatment responses, or provide information on disease genetic susceptibility.

MARKET OVERVIEW

The genomic biomarker market is valued at approximately USD 26.78 billion in 2024 and is projected to reach USD 89.56 billion by 2035 exhibiting a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2025-2035. The concept of genomic biomarkers has become increasingly popular in the field of personalized medicine, which involve understanding person's distinct genetic composition to maximize therapeutic approaches and reduce side effects.

GROWTH DRIVERS

The pharmaceutical industry is witnessing an increase in the use of genetic testing for inherited disorders, rare diseases, and cancer. Genomic biomarkers play a vital role in oncology, as they are crucial for tumor profiling, minimal residual disease (MRD) testing, and liquid biopsies, which aid in matching patients with targeted therapies and immunotherapies. For example, cancer has become the dominant segment in the genomic biomarkers market due to the rapid adoption of these applications. Hospitals and labs are investing more in genomics platforms and services due to the growing number of patients getting genomic testing for these disorders. For example, in August 2024, FDA approved Illumina's TruSight™ Oncology Comprehensive test, which analyzes more than 500 genes in solid tumors, which demonstrates the crucial role that genomic testing plays in guiding the selection of targeted therapies.

The rising frequency of chronic diseases such as cancer, cardiovascular disease, and neurological disorders worldwide is creating a significant need for precise and timely diagnostic instruments. Genomic biomarkers provide a level of accuracy that conventional techniques frequently lack, resulting in better patient care and more successful treatment approaches.

According to the National Institutes of Health, chronic diseases are among the leading causes of morbidity and mortality globally, which is driving up demand for genetic biomarkers. For example, genomic biomarkers are frequently used in oncology to choose patients for targeted therapies, such as EGFR mutation testing for non-small cell lung cancer to direct treatment with tyrosine kinase inhibitors or HER2 testing for breast cancer patients to determine eligibility for trastuzumab.

MARKET SEGMENTATION:

By Product Type -

·         Consumables

o   Assay Kits

o   Reagents & Chemicals

o   Columns & Filters

·         Services

·         Software

By Type –

·         Safety Biomarkers

·         Efficacy Biomarkers

·         Predictive Biomarkers

·         Surrogate Biomarkers

·         Pharmacodynamics Biomarkers

·         Prognostic Biomarkers

·         Validation Biomarker

By Technology –

·         Next-Generation Sequencing (NGS)

·         Polymerase Chain Reaction (PCR)

·         Microarrays

·         Genomic Hybridization

·         Other Technologies

By Application –

·         Oncology 

·         Rare Genetic Disorders & Metabolic Diseases

·         Infectious Diseases

·         Immunological Disorders

·         Neurological Disorders

·         Cardiovascular Disorders

·         Autoimmune & Inflammatory Disorders

·         Pharmacogenomics & Personalized Medicine

·         Other Disease Indication

By End User –

·         Hospitals & Clinical Diagnostic Laboratories

·         Pharmaceutical & Biotechnology Companies

·         Academic & Research Institutes

·         Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs)

·         Other End Users

By Region -

·         North America

·         Europe

·         Asia Pacific

·         Latin America

·         Middle East & Africa

Market By Product Type Segment Review:

In 2024, consumables segment is expected to hold the largest share of the market due to its frequent and crucial application in both clinical diagnostics and scientific research. They are essential to all stages of genomic analysis, including sample-preparation, sequencing, and detection.

Market By Type Segment Review:

Safety biomarkers serve as indicators to evaluate the potential for negative effects or toxicity of a drug or therapy. In the context of genomics, these indicators enable prediction of a person's reaction to a medication that is likely to cause negative reactions or detect genetic predispositions to specific side effects.

Market By Technology Segment Review:

With NGS technology, millions of DNA fragments are sequenced simultaneously, which offers a thorough understanding of genetic variations, including structural variants, insertions, deletions, and single nucleotide polymorphisms (SNPs). In cancer genomics, NGS systems are frequently used to detect germline predispositions, identify somatic mutations, and evaluate treatment response.

Market By Application Segment Review:.

In the market for genetic biomarkers, oncology is the largest and most rapidly growing application segment. In cancer, genomic biomarkers are widely employed for early detection, diagnosis, prognosis, treatment response prediction, and minimal residual disease monitoring.

Market By End User Segment Review:

In 2024, hospitals & clinical diagnostic laboratories segment dominated the market, driven by their direct involvement in patient diagnosis, prognosis, and therapy selection. The growing integration of precision medicine into clinical practice, especially in oncology, infectious diseases, and rare genetic disorders, fuels this segment's dominance.

Market By Region Segment Review:

The genomic biomarker market exhibits significant regional variations, with North America leading the market in 2024 due to its robust healthcare infrastructure, high adoption of advanced genomic technologies, significant R&D investments, and favorable reimbursement policies.

Regional Synopsis:

North America is poised for continuous growth, primarily driven by the growing use of genomic testing in oncology, rare diseases, and inherited disorders, rapid advancements in NGS and PCR technologies, increasing demand for personalized medicine, regulatory approvals and favorable policies, strategic partnerships and collaborations, and integration of AI and machine learning.

Europe also represents a significant market for genomic biomarker, supported by the combination of increasing demand for personalized medicine, technological advancements, and a rising prevalence of chronic diseases across the region.

Asia-Pacific market is anticipated to experience the highest CAGR during the forecast period from 2025 to 2035, driven by the rising cancer burdens, national precision-medicine initiatives, and the expansion of NGS-enabled hospital labs.

The Latin American market is experiencing substantial growth, fueled by the advancements in precision medicine, increasing prevalence of chronic diseases, and rising adoption of personalized treatment approaches.

The market expansion in the MEA region is driven by the increasing prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer, which have heightened the demand for personalized diagnostic and therapeutic solutions.

Key Challenges:

The high cost of advanced genomic testing is likely to act as the most significant barriers to wider adoption of genomic biomarker. Despite the decline in sequencing costs, the cost of comprehensive genomic biomarker testing remains high, particularly for data interpretation and clinical validation. The accessibility of genomic testing and targeted therapies often becomes limited for many patients due to their high upfront cost and inconsistent reimbursement policies.

Competitive Landscape:

The global genomic biomarker market is characterized by mix of established players, each striving to enhance their market presence through various strategies such as product launches and approvals, strategic partnerships and collaborations, mergers and acquisitions, expansion into new applications, and growing focus on end-to-end service models.

Manufacturers strongly product innovation and portfolio diversification in this market. Companies are making significant investments in R&D to maintain a technological edge. This includes developing technologies like NGS system. NGS advancements are designed to lower prices, boost accuracy, and speed up turnaround times, increasing the efficiency and accessibility of genomic testing.

Key Players:

·         Bio-Rad Laboratories

·         Almac Group

·         Eurofins Scientific

·         Thermo Fisher Scientific Inc

·         Epigenomics AG

·         Roche Diagnostics

·         Myriad Genetics

·         QIAGEN

·         Other Key & Niche Players